B4GALNT2 and colonic neoplasm: The antigen has been suggested to be used as a colon tumor marker due to its downregulation in cancerous tissue in favor of the sialyl-Lewis X (sLex) epitope, the synthesis of which utilizes the same sialylated precursors as those of the Sda epitope [17].